
Developing Multi-Targeted T-Cell Engagers With Deck Bio’s Johanna Kaufmann
In this episode of “Better Biopharma,” host Tyler Menichiello is joined by Deck Bio’s chief scientific officer, Johanna Kaufmann, to discuss the company’s multi-peptide-MHC-targeted T-cell engager platform for solid tumors. Kaufmann explains the platform and reflects on the company’s journey through preclinical development.
Keep up with everything biomanufacturing at Bioprocess Online: https://www.bioprocessonline.com/
Follow Tyler Menichiello on LinkedIn: https://www.linkedin.com/in/tmenichiello/
Subscribe to our newsletters: https://www.bioprocessonline.com/user/edit/subscriptions
Tell us how we can improve. Take our 60-second survey: https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header
Otros episodios de "Better Biopharma"



No te pierdas ningún episodio de “Better Biopharma”. Síguelo en la aplicación gratuita de GetPodcast.








